Patricia L. Allen - Jan 17, 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role
Director
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Stock symbol
DCPH
Transactions as of
Jan 17, 2023
Transactions value $
$50,000
Form type
4
Date filed
1/19/2023, 03:05 PM
Previous filing
Jun 24, 2022
Next filing
Jun 23, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCPH Stock Option (Right to Buy) Award $50K +3.27K $15.30 3.27K Jan 17, 2023 Common Stock 3.27K $21.27 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options were issued upon election by the director to receive her cash board retainer fee of $50,000 for the FY 2023 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. The shares will vest in four substantially equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023.